Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Relay Therapeutics Inc. Common Stock — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Definium Therapeutics Inc. Common Shares is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| DFTX | RLAY | |
|---|---|---|
Market Cap | $4.71B | $3.94B |
Volume | 1,966,636 | 3,432,928 |
Sector | Health | Health |
52-Week High | $48.45 | $20.75 |
52-Week Low | $10.68 | $6.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.67B | $3.06B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
